Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.51 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.39 |
| ▸ | LGALS8 | O00214 | 3/20 | 0.37 |
| ▸ | OGA | O60502 | 1/20 | 0.35 |
| ▸ | LGALS1 | P09382 | 2/20 | 0.35 |
| ▸ | LGALS3 | P17931 | 2/20 | 0.35 |
| ▸ | LGALS9 | O00182 | 1/20 | 0.35 |
| ▸ | PYGB | P11216 | 2/20 | 0.35 |
| ▸ | GAA | P10253 | 2/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15353306 | 0.92 | SLC2A1 (0.44) | SLC2A1MAPK1LGALS8OGALGALS1 | |
| SCHEMBL10389647 | 0.92 | SLC2A1 (0.44) | SLC2A1MAPK1LGALS8OGALGALS1 | |
| SCHEMBL8993023 | 0.86 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8LGALS1LGALS3 | |
| SCHEMBL7934598 | 0.86 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8LGALS1LGALS3 | |
| SCHEMBL9271392 | 0.86 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8LGALS1LGALS3 | |
| SCHEMBL8396723 | 0.86 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8LGALS1LGALS3 | |
| SCHEMBL18173519 | 0.86 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8LGALS1LGALS3 | |
| SCHEMBL8992715 | 0.86 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8LGALS1LGALS3 | |
| SCHEMBL14855691 | 0.85 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8OGALGALS1 | |
| SCHEMBL14856007 | 0.85 | SLC2A1 (0.40) | SLC2A1MAPK1LGALS8OGALGALS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | BARCLAYS BANK PLC (GB) | 2022-01-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220017535-A1 | INHIBITORS OF ALDOSE REDUCTASE | PMM2, DPM1, BPGM | SLC2A1 473/4885MAPK1 1805/4885LGALS8 393/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.